Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV)

References

• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. New England Journal of Medicine 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Freedman A S, Gribben J G, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88(7)2780–2786
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87–2. Groupe d'Etude des Lymphomes de l'Adulte. Journal of Clinical Oncology 1997; 15(3)1131–1137
   PubMed Web of Science ®Google Scholar
• Deeg H J, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91(6)1833–1844
   PubMed Web of Science ®Google Scholar
• Rohatiner A. Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation [editorial]. Journal of Clinical Oncology 1994; 12(12)2521–2523
   PubMed Web of Science ®Google Scholar
• Stone R M. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress [editorial]. Blood 1994; 83(12)3437–3440
   PubMed Web of Science ®Google Scholar
• Stone R M, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Journal of Clinical Oncology 1994; 12(12)2535–2542
   PubMed Web of Science ®Google Scholar
• Miller J S, Arthur D C, Litz C E, Neglia J P, Miller W J, Weisdorf D J. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy [see comments]. Blood 1994; 83(12)3780–3786
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemora-diotherapy and autologous stem-cell transplantation for lymphoid malignancies. Journal of Clinical Oncology 1994; 12(12)2527–2534
   PubMed Web of Science ®Google Scholar
• De Witte T, Zwaan F, Hermans J, et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). BrJ Haematol 1990; 74(2)151–155
   PubMed Web of Science ®Google Scholar
• Bashir S, Cook P, Katz M, Mittelman A, Ahmed T. Allogeneic marrow transplantation for myelodysplastic syndrome complicating autologous bone marrow transplantation. Cancer Investigation 1994; 12(5)484–487
   PubMed Web of Science ®Google Scholar
• Lowsky R, Lipton J, Fyles G, et al. Secondary malignancies after bone marrow transplantation in adults. Journal of Clinical Oncology 1994; 12(10)2187–2192
   PubMed Web of Science ®Google Scholar
• Curtis R E, Rowlings P A, Deeg H J, et al. Solid cancers after bone marrow transplantation [see comments]. New England Journal Of Medicine 1997; 336(13)897–904
   PubMed Web of Science ®Google Scholar
• Mauch P M, Kalish L A, Marcus K C, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996; 87(9)3625–3632
   PubMed Web of Science ®Google Scholar
• Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal of Clinical Oncology 1996; 14(9)2435–2443
   PubMed Web of Science ®Google Scholar
• Travis L B, Weeks J, Curtis R E, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. Journal of Clinical Oncology 1996; 14(2)565–571
   PubMed Web of Science ®Google Scholar
• Curtis R E, Boice J DJ, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. New England Journal of Medicine 1992; 326(26)1745–1751
   PubMed Web of Science ®Google Scholar
• Shipp M A, Neuberg D, Janicek M, Canellos G P, Shulman L N. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Journal of Clinical Oncology 1995; 13(12)2916–2923
   PubMed Web of Science ®Google Scholar
• Wheeler C, Antin J H, Churchill W H, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Journal of Clinical Oncology 1990; 8(4)648–656
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hollander M, Wolfe D A. Nonparametric Statistical Methods. New York: Wiley 1973
   Google Scholar
• Rosner B. Fundamentals of Biostatistics. Boston: PWS-Kent 1990
   Google Scholar
• Cox D. Regression models and life tables. Journal of the Royal Statistical Society 1972; 33: 187–220
   Google Scholar
• Legare R D, Gribben J G, Maragh M, et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelo-dysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. American Journal of Hematology 1997; 56(1)45–51
   PubMed Web of Science ®Google Scholar
• Abkowitz J L, Catlin S N, Guttorp P. Strategies for hematopoietic stem cell gene therapy: insights from computer simulation studies. Blood 1997; 89(9)3192–3198
   PubMed Web of Science ®Google Scholar
• Sawada K, Leko M, Notoya A, et al. Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells. Blood 1996; 88(l)319–327
   PubMed Web of Science ®Google Scholar
• Tucker M A, Coleman C N, Cox R S, Varghese A, Rosenberg S A. Risk of second cancers after treatment for Hodgkin's disease. New England Journal of Medicine 1988; 318(2)76–81
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak M L, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors [In Process Citation]. Blood 2000; 95(5)1588–1593
   PubMed Web of Science ®Google Scholar
• Micallef I NM, Lillington D M, Apostolidis J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. Journal of Clinical Oncology 2000; 18: 947–955
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. Journal of Clinical Oncology 1999; 17: 3374–3388
   PubMed Web of Science ®Google Scholar